The Nordic Society of
Investigator Meeting 2022
ESMO 2022 – Line Bjørge: Some of the patients with ovarian cancer who received olaparib were cured. The SOLO-1 study shows that 67 percent of patients with advanced ovarian cancer with BRCA mutations who were treated with the PARP inhibitor Olaparib were alive after 7 years compared to 47 percent in the placebo group. – Some of the patients with ovarian cancer who received olaparib were cured. This is a big step forward for our patients.
Mansoor Raza Mirza, MD, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, discusses recent improvements in immune-oncology, specifically immune checkpoint inhibitors, for patients with endometrial or cervical cancer. There have been big developments in this field in recent years, with several therapies being approved in the EU and USA. Several Phase III trials are likely to produce interesting data in the near future. This interview took place at the European Society of Gynaecological Oncology (ESGO) 2021 congress in Prague
Results of ENGOT-EN6/GOG-3031/NSGO-RUBY study: A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer Results of ENGOT-EN6/GOG-3031/NSGO-RUBY study: A Study